Talking Medicines joins 2026 UK AI Index

Tern plc

Talking Medicines has been named in the 2026 UK AI Index, placing it among the top 1,000 AI companies in the country.

The company’s core offering focuses on converting unstructured healthcare dialogue into structured, actionable intelligence for pharmaceutical clients. By applying natural language processing and machine learning to patient and healthcare professional conversations, Talking Medicines helps pharma teams improve how they position medicines, understand brand performance and engage with clinicians. This use of real-world voice data offers a practical solution to the ongoing challenge of making sense of fragmented health communications.

Recognition by the UK AI Index gives Talking Medicines a stronger position within a national network of AI companies that are attracting attention from both investors and policymakers. The index is supported by government and industry groups aiming to map out leadership in artificial intelligence across sectors such as health, finance and energy.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Messaging precision becomes a commercial lever for pharma in 2026

As patent pressures mount and new therapies launch, the ability to measure message resonance is becoming central to pharma commercial strategy.

Tern Plc secures extension on £120,000 loan balance

Tern PLC has extended the repayment date of its loan facility to 11 September 2026, providing additional flexibility as it plans funding for investee companies. £120,000 plus monthly interest remains payable following a partial repayment.

Tern Plc issues 78.2m shares following Open Offer

Tern Plc announced valid acceptances for 78,163,662 Open Offer Shares at 0.40 pence per share, generating gross proceeds of about £312,654. The enlarged share capital will total 750,877,367 ordinary shares upon admission to AIM.

Fundamental XR expands access to immersive training with web-enabled platform

Its new Immersive Web platform brings immersive training into the browser, lowering adoption barriers and broadening enterprise reach.

GLP-1 receptor agonists: Strategic market shift

Rapid uptake, evolving regulation and digital integration are reshaping the investment case for metabolic health therapies.

The Cyber Resilience Act forces a security reset for connected device makers

Device Authority helps manufacturers operationalise Cyber Resilience Act compliance through automated device identity and secure update management.

Search